REDWOOD CITY, Calif., Aug. 23, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview at the following investor conferences:
2012 Southern California Investor Conference
Date: Thursday, August 30, 2012 at 1:30 p.m. PDT (4:30 p.m. EDT)
Location: Marriott-Newport Beach, Newport Beach, Calif.
Stifel Nicolaus Healthcare Conference 2012
Date: Thursday, September 6, 2012 at 9:10 a.m. EDT (6:10 a.m. PDT)
Location: The Four Seasons Hotel, Boston, Mass.
Rodman & Renshaw Annual Global Investment Conference
Date: Tuesday, September 11, 2012 at 9:35 a.m. EDT (6:35 a.m. PDT)
Location: The Waldorf Astoria, New York City, N.Y.
All presentations will be webcast live and can be accessed through the investor relations page at www.acelrx.com. For those not available to listen to the live broadcast, a replay of the presentations will be archived and available through www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is currently in Phase 3 clinical development, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV rout
|SOURCE AcelRx Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved